What is the current price and volume for NOVN.SW stock?

Pre-market on 13 Feb 2026 Novartis (NOVN.SW stock) trades at **CHF123.80** with volume **3,264,104.00**, above the average **3,167,190.00**, reflecting high liquidity on the SIX.

How does Meyka rate NOVN.SW stock and what does it mean?

Meyka AI rates NOVN.SW with a score of **77.84** (Grade B+, suggestion: BUY). The grade combines benchmark, sector, growth and analyst factors. This is informational and not investment advice.

What short-term price target does Meyka provide for NOVN.SW stock?

Meyka AI's forecast model projects **CHF127.28** for the quarter, which implies an approximate **2.81%** upside from the current **CHF123.80**. Forecasts are model-based projections and not guarantees.

What are the main risks for NOVN.SW stock investors?

Key risks for NOVN.SW stock include regulatory setbacks, clinical trial outcomes, patent expiries and currency moves. Earnings surprises around the April report can produce strong short-term volatility.

CH Stocks

Pre-market Most Active: NOVN.SW Novartis (SIX) CHF123.80 13 Feb 2026: Watch upside

ByDanny Kontos February 13, 2026

Novartis AG’s NOVN.SW stock is trading at CHF123.80 pre-market on 13 Feb 2026. Volume is already 3,264,104.00 shares, above the average of 3,167,190.00, which puts the name among the most active on the SIX today. The share price sits near its year high of CHF124.18 after a year-to-date gain of 14.10%, driven by steady fundamentals and renewed investor interest in the Healthcare sector. This pre-market note highlights price action, valuation, Meyka grade and short-term technical signals to help frame trading and investment decisions.